Petros Pharmaceuticals announces online distribution for lead ED product with Lemonaid Health
April 25, 2024 at 10:21 am
Share
(via NewsDirect)
Petros Pharmaceuticals CEO Fady Boctor joined Steve Darling from Proactive to share exciting developments with Proactive, highlighting a new collaboration with Lemonaid Health, a prominent telemedicine provider and subsidiary of 23andMe. Through this collaboration, Lemonaid Health's telehealth platform will offer prescription STENDRA® (avanafil) in all strengths, expanding distribution and enhancing access for patients. Lemonaid Health's extensive reach, having treated over 200,000 patients with erectile dysfunction (ED) to date, positions Petros to serve a broader patient base across the United States effectively.
In addition to the collaboration with Lemonaid Health, Boctor discussed the positive results of an initial cohort in Petros' self-selection study. This study compares the use of a Drug Facts Label (DFL) alone to a combination of DFL with a web app. The preliminary results suggest that while the DFL-alone approach may be insufficient for self-selection, the combination with the proposed technology significantly improves outcomes. This study serves as a precursor to Petros' pivotal Phase 2 study, initiated earlier this month, which aims to provide compelling evidence to the FDA. The pivotal study is designed to demonstrate that users can determine the appropriateness of STENDRA® (avanafil) without the need for a physician and prescription.
These developments underscore Petros Pharmaceuticals' commitment to leveraging innovative solutions to improve patient access to essential medications and streamline healthcare delivery processes.
Contact Details
Proactive North America
Proactive North America
+1 604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2024 TheNewswire - All rights reserved.
Copyright (c) 2024 TheNewswire - All rights reserved., source Press Releases
Petros Pharmaceuticals, Inc. is a pharmaceutical company focused on men's health therapeutics with a range of commercial capabilities including sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. The Company is also focused on identifying, developing, acquiring, and commercializing therapeutics for men's health issues, including, erectile dysfunction (ED), endothelial dysfunction, psychosexual and psychosocial ailments, peyronie's disease, hormone health, and substance use disorders. The Company also markets its own line of ED products in the form of vacuum erection device (VED) products through its subsidiaries, Timm Medical, Inc. In addition, its ED products, the Company is focused on identifying and developing other pharmaceuticals to advance men's health, which is H100, which is the topical formulation candidate for the treatment of acute peyronie's disease.